Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...

Jared Holz, Mizuho, joins 'Fast Money' to talk how possible Medicare price negotiations are impacting Novo Nordisk shares.

As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for kids ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...